CWM
LTRN icon

Cranbrook Wealth Management’s Lantern Pharma LTRN Stock Holding History

Cranbrook Wealth Management’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-717
Closed -$3.46K – 290
2023
Q1 		$3.46K Buy
+717
New +$3.77K ﹤0.01% 264

Other funds holding LTRN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cranbrook Wealth Management's LTRN Position: Q2 2023 in Review

Cranbrook Wealth Management sold out of Lantern Pharma (LTRN) in Q2 2023, closing a stake of 717 shares — an estimated $3.46K sold.

Cranbrook Wealth Management first reported a position in LTRN in Q1 2023 and held it in 1 quarter. The position peaked at $3.46K in Q1 2023. 25 funds tracked by Wall St. Rank hold LTRN as of Q2 2023.

  • Cranbrook Wealth Management reported no remaining Lantern Pharma position as of Q2 2023 after selling out during the quarter.
  • Cranbrook Wealth Management sold 717 Lantern Pharma shares in Q2 2023, an estimated $3.46K.
  • Cranbrook Wealth Management first reported a position in Lantern Pharma in Q1 2023 and held it in 1 quarter.
  • Cranbrook Wealth Management's Lantern Pharma position peaked at $3.46K in Q1 2023.
  • 25 funds tracked by Wall St. Rank held Lantern Pharma as of Q2 2023.

Based on Cranbrook Wealth Management's 13F filing for Q2 2023, filed 17 Jul 2023.